Clinical Cancer Research Archives
Study identifies biomarker for breast cancer response to immunotherapy
Aug. 12, 2021—A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Study explores melanoma drug’s effectiveness
Apr. 23, 2020—A study by Vanderbilt research-ers supports the clinical development of a new second-line treatment for metastatic melanoma.
Breast cancer study may help predict treatment response
Feb. 27, 2020—Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.
Study finds breast cancer recurrence score has different implications for men
Nov. 20, 2019—A study published last year offered good news for women with early-stage ER-positive breast cancer who scored at intermediate risk for recurrence. However, a new study finds this conclusion may not directly apply to male patients with the same type of breast cancer
Study reframes approach to targeted therapy resistance
Apr. 11, 2019—When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.
Improving therapies for GI tumors
Feb. 20, 2017—A signaling protein overexpressed in upper gastrointestinal cancers is an attractive therapeutic target.
Drug combos for glioblastoma
May. 3, 2016—Vanderbilt researchers have discovered that activation of a certain signaling pathway protects brain cancers from targeted therapies, suggesting that using therapeutics that block both pathways may be a promising treatment.
Five candidates sought for Runyon Cancer Clinical Investigator Award
Nov. 13, 2015—Vanderbilt University may nominate five candidates for the 2016 Damon Runyon Cancer Research Foundation Clinical Investigator Award.
PET probe detects dying tumor cells
May. 8, 2014—A novel PET imaging probe detects tumor cell death in vivo and could be useful for personalizing cancer medicine.
New drugs a good BET for brain cancer
Mar. 20, 2013—A novel class of drugs that target “BET” proteins may have broad utility for treating genetically diverse brain tumors.
New drug mutes more melanomas
Apr. 26, 2012—An experimental melanoma drug may be beneficial for patients not eligible for targeted therapies.
Factor sensitizes cancer to radiation
Apr. 6, 2012—Measuring levels of an enzyme in head and neck tumors may indicate how the tumor will respond to radiation therapy.
